The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV).
Dr Fagan Bellows and colleagues assessed the development of anal carcinoma in patients with HIV.
The researchers determined if the duration of HIV disease or the patient's immune status were associated with anal carcinoma.
HIV-positive patients diagnosed with anal neoplasms were reviewed.
The research team performed statistical analysis via an unpaired Student t test and the Fisher exact test.
|Anal carcinoma will become an increasing problem with improved survival from new HIV therapy|
|American Journal of Surgery|
The researchers identified 14 patients, of which 7 with anal intraepithelial neoplasms were in Group 1, and 7 with anal carcinoma were in Group 2.
The team detected human papillomavirus in 100% of patients in Group 1 and in 67% of patients in Group 2.
There was no significant difference in the level of immunosuppression as assessed by the CD4 counts and viral loads between Groups 1 and 2, respectively.
The team reported that Group 2 had been HIV positive for a significantly longer period of time compared with Group 1.
Dr Bellows' team concluded, “The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease.”
“As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.”